Clinical Trial Update: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing trifluridine/tipiracil combined with oxaliplatin and bevacizumab vs XELOX plus bevacizumab in first-line advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• OXALIPLATIN (Oxaliplatin)
• XELOX (capecitabine + oxaliplatin)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: First-line Treatment, Advanced Colorectal Cancer | Phase 2 | Status: UNKNOWN